Lack of Correlation Between Methotrexate Concentrations in Serum, Saliva and Sweat After 24 H Methotrexate Infusions

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1987 Oct 1

PMID 3689633

Citations 4

Authors

H Schroder

K B Jensen

M Brandsborg

Affiliations

Soon will be listed here.

Abstract

1 Methotrexate (MTX) concentrations were studied in serum, mixed saliva and sweat during and after 24 h continuous MTX infusions (0.5-6 g m-2) in 14 patients with various malignant diseases. 2 The serum-MTX concentrations declined in a biphasic manner, but the MTX elimination in saliva and sweat varied to a much greater extent. 3 Saliva/serum and sweat/serum ratios during the MTX infusion were 2.3% and 0.55% respectively. The ratios had increased significantly 20 and 44 h postinfusion. 4 No correlations were demonstrated between salivary- and serum-MTX concentrations during the MTX infusion or 20 and 44 h later. 5 Markedly delayed renal MTX excretions were demonstrated in two patients. In one of them the salivary MTX elimination was also retarded, whereas this was not seen in the other one. 6 We conclude that measurements of MTX concentrations in mixed saliva cannot substitute for serum-MTX determinations in the monitoring of patients after 24 h MTX infusions.

Citing Articles

Saliva as a Future Field in Psoriasis Research.

Asaad F, Fiore M, Alfieri A, Pigatto P, Franchi C, Berti E Biomed Res Int. 2018; 2018:7290913.

PMID: 29888276 PMC: 5985113. DOI: 10.1155/2018/7290913.

Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics.

Murakami T, Mori N Pharmaceuticals (Basel). 2013; 5(8):802-36.

PMID: 24280676 PMC: 3763673. DOI: 10.3390/ph5080802.

Critical factors for the reversal of methotrexate cytotoxicity by folinic acid.

Bernard S, Etienne M, Fischel J, Formento P, Milano G Br J Cancer. 1991; 63(2):303-7.

PMID: 1997110 PMC: 1971778. DOI: 10.1038/bjc.1991.70.

Therapeutic drug monitoring in saliva. An update.

Drobitch R, Svensson C Clin Pharmacokinet. 1992; 23(5):365-79.

PMID: 1478004 DOI: 10.2165/00003088-199223050-00003.

References

Juma F, Rogers H, Trounce J . The kinetics of salivary elimination of cyclophosphamide in man. Br J Clin Pharmacol. 1979; 8(5):455-8. PMC: 1429824. DOI: 10.1111/j.1365-2125.1979.tb01025.x. View

Rechnitzer C, Scheibel E, Hendel J . Methotrexate in the plasma and cerebrospinal fluid of children treated with intermediate dose methotrexate. Acta Paediatr Scand. 1981; 70(5):615-8. DOI: 10.1111/j.1651-2227.1981.tb05755.x. View

Patterson A, Ritschel W, Zellner D, Kim S . Methotrexate serum and saliva concentrations in patients. Int J Clin Pharmacol Ther Toxicol. 1981; 19(9):381-5. View

Steele W, Lawrence J, Stuart J, McNeill C . The protein binding of methotrexate in the serum of patients with neoplastic disease. Cancer Chemother Pharmacol. 1981; 7(1):61-4. DOI: 10.1007/BF00258215. View

Paxton J . Protein binding of methotrexate in sera from normal human beings: effect of drug concentration, pH, temperature, and storage. J Pharmacol Methods. 1981; 5(3):203-13. DOI: 10.1016/0160-5402(81)90088-7. View

Kamen B, Takach P, Vatev R, CASTON J . A rapid, radiochemical-ligand binding assay for methotrexate. Anal Biochem. 1976; 70(1):54-63. DOI: 10.1016/s0003-2697(76)80047-4. View

Evans W, Pratt C, Taylor R, Barker L, Crom W . Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Cancer Chemother Pharmacol. 1979; 3(3):161-6. DOI: 10.1007/BF00262416. View

di SantAgnese P, DARLING R, PERERA G, Shea E . Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas; clinical significance and relationship to the disease. Pediatrics. 1953; 12(5):549-63. View

Imbert A, Pignon T, Lena N . Enzymatic assay for methotrexate with a centrifugal analyzer (Cobas-Bio). Clin Chem. 1983; 29(6):1317-8. View

10.

Ritschel W, Bykadi G, Norman E, Cluxton R, Denton D . Salivary elimination of cyclophosphamide in man. J Clin Pharmacol. 1981; 21(11):461-5. DOI: 10.1002/j.1552-4604.1981.tb05650.x. View

11.

Jolivet J, Cowan K, Curt G, Clendeninn N, Chabner B . The pharmacology and clinical use of methotrexate. N Engl J Med. 1983; 309(18):1094-104. DOI: 10.1056/NEJM198311033091805. View

12.

Steele W, Stuart J, Whiting B, Lawrence J, Calman K, McVie J . Serum, tear and salivary concentrations of methotrexate in man. Br J Clin Pharmacol. 1979; 7(2):207-11. PMC: 1429434. DOI: 10.1111/j.1365-2125.1979.tb00923.x. View

13.

Stoller R, Hande K, Jacobs S, Rosenberg S, Chabner B . Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977; 297(12):630-4. DOI: 10.1056/NEJM197709222971203. View

14.

Danhof M, Breimer D . Therapeutic drug monitoring in saliva. Clin Pharmacokinet. 1978; 3(1):39-57. DOI: 10.2165/00003088-197803010-00003. View